Rumor Mill: Is BMS going on the sales block?
With Peter Dolan out the door at Bristol-Myers Squibb, the choice for his interim successor is already sparking rumors that the company could be up for sale. James M. Cornelius helped orchestrate the Guidant buyout in his last post, which would make him the ideal person to negotiate a sale of BMS, analysts say. If nothing else, rumors of a takeover could be enough to put the company into play. Of course, this is all pure speculation, which Wall Street loves. But on Wall Street, today's hot rumor is often tomorrow's headline.
- read the article on BMS from The Wall Street Journal (sub. req.)
More stories about Bristol-Myers Squibb
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
